• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

    6.930 -0.040 (-0.57%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Recursion Pharmaceuticals Inc Cl A

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    How Is The Market Feeling About Recursion Pharmaceuticals?
    Via Benzinga
    The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
    Merging with a former rival will bolster its capabilities. 
    Via The Motley Fool
    Is Recursion Pharmaceuticals Stock a Buy?
    We'll know a little more about the biotech's prospects in a year and a half. 
    Via The Motley Fool
    AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
    The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
    Via Talk Markets
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
    Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT 
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    From FN Media Group LLC
    Via GlobeNewswire
    Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
    Efficiency in core processes is set to increase substantially due to AI. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
    There isn't much to suggest these businesses are actually vulnerable. 
    Via The Motley Fool
    Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
    The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
    Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million... 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024
    RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
    Operational complementarities expected to yield annual synergies of approximately $100 million 
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Is Recursion Pharmaceuticals a Millionaire-Maker?
    It's likely to experience a lot of growth. 
    Via The Motley Fool
    99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks
    Artificial intelligence (AI) colossus Nvidia has stakes in five publicly traded companies -- four of which account for almost every cent of its AI-driven portfolio. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
    Via Talk Markets
    Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
    There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    25 Best Artificial Intelligence Stocks to Buy Right Now
    Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
    This article identifies the 
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    3 Millionaire-Maker Artificial Intelligence (AI) Stocks
    For the next stage of the AI era, companies with purposeful, practical, and highly targeted solutions stand to benefit the most. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
    Via Talk Markets
    Is Recursion Pharmaceuticals Stock a Buy?
    The company is ambitious and exploring exciting areas, but it's still early in the game. 
    Via The Motley Fool
    1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
    This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump. 
    Via The Motley Fool
    3 Healthcare Stocks Injecting AI for Big Gains
    Investors should keep a close eye on these AI healthcare stocks as they revolutionize the future of drug development and patient care. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.